DNA icon

Developmental and Epileptic Encephalopathy via the GRIN2D Gene

Summary and Pricing

Test Method

Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
GRIN2D 81479 81479,81479 $990
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
13043GRIN2D81479 81479,81479 $990 Order Options and Pricing

Pricing Comments

Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.


Genetic Counselors


  • Eric Bend, PhD

Clinical Features and Genetics

Clinical Features

GRIN2D-related developmental and epileptic encephalopathy is a rare disorder which presents within the first year of life.  The first cases described were diagnosed with early infantile epileptic encephalopathy-46 (EIEE46, Li et al. 2016. PubMed ID: 27616483; Tsuchida et al. 2018. PubMed ID: 30280376).  The phenotype was later expanded to include developmental delay and additional neurological features (XiangWei et al. 2019. PubMed ID: 31504254).  Major features (documented in >50% of cases) include severe global developmental delay, intellectual disability, hypotonia, and various, often intractable, seizures.  Minor features of GRIN2D-related disease (<50% of cases) include mild dysmorphic features, autistic behaviors, attention deficit disorder, microcephaly, movement disorders and oculomotor apraxis.  Most patients have normal MRIs, but abnormalities have included loss of white matter volume, dilated ventricles, thin corpus callosum, and cerebral atrophy (XiangWei et al. 2019. PubMed ID: 31504254; Tsuchida et al. 2018. PubMed ID: 30280376; Li et al. 2016. PubMed ID: 27616483; Camp and Yuan. 2020. PubMed ID: 31918992).

A diagnosis of GRIN2D-related developmental and epileptic encephalopathy can provide prognostic information and guide pharmacological therapy.  This disorder results in profound disability and reduced life expectancy (Camp and Yuan. 2020. PubMed ID: 31918992).  Conventional anti-epileptics drugs used in combinations have proven effective in reducing seizure activity in some individuals (i.e. valproate, topiramate, ethylloflazepate, levetiracetam, clonazepam, and oral steroids; Camp and Yuan. 2020. PubMed ID: 31918992). In addition, targeted NMDA suppression has shown some promise- the pore-blocker memantine reduced seizure activity in two of three patients with gain-of-function variants (Li et al. 2016. PubMed ID: 27616483; XiangWei et al. 2019. PubMed ID: 31504254). Finally, early evidence suggests that immunotherapy may be effective in reducing seizure activity (Hausman-Kedem et al. 2020. PubMed ID: 32289570).


GRIN2D-related disease is autosomal dominant and apparently fully penetrant—to date nearly all cases have involved de novo missense variants.

Pathogenic variants in GRIN2D are enriched in three functional protein domains including the pre-M1 helix, M3 transmembrane motif, and carboxyl-terminal domain (XiangWei et al. 2019. PubMed ID: 31504254). The coding sequence is moderately intolerant to missense variation based on data from gnomAD, and the three regions listed above are particularly depleted of natural missense variation (XiangWei et al. 2019. PubMed ID: 31504254). At least one recurrent de novo variant in the M3 domain (c.1999G>A, p.Val667Ile) has been reported in three unrelated individuals  (Li. 2016. PubMed ID: 27616483 Xiang Wei et al. 2019. PubMed ID: 31504254). Haploinsuficiency due to chain-terminating variants is not an established mechanism of disease; however, there is limited evidence associating this mechanism with autism spectrum disorder and schizophrenia (Yu. 2018. PubMed ID: 29317596).

GRIN2D(GluN2D)-knockout mice are viable and overtly normal. However, close examination revealed they have mild differences in locomotor phenotype and spatial memory, as well as altered monoamine levels, cellular electrophysiology characteristics, and interneuron histology (Camp and Yuan. 2020. PubMed ID: 31918992). Therefore, this gene is not essential for cellular function. Instead, it appears to be required for regulating complex neurodevelopmental functions of vertebrate organisms.  

GRIN2D encodes the alpha-2 subunit of NMDA receptors. These ligand-gated ion channels bind glutamate and glycine and serve as important detectors of activity for synaptic plasticity, learning, and memory. NMDA receptors are heterotetrameric, composed of one alpha-1 subunit and one or more alpha-2 A, B, C, or D subunit.  This composition is dependent on developmental timing (Camp and Yuan. 2020. PubMed ID: 31918992).

Clinical Sensitivity - Sequencing with CNV PG-Select

The clinical sensitivity of this test alone is expected to be low (<1%). GRIN2D-related developmental and epileptic encephalopathy is an ultra-rare disorder with only 16 unique missense variants reported to date. In addition, there are approximately one hundred genes associated with similar epileptic encephalopathy phenotypes. However, since all well-characterized pathogenic variants in GRIN2D are single base pair substitutions, the analytical sensitivity of this test is predicted to be very high (>99%).

Testing Strategy

This test is performed using Next-Generation sequencing with additional Sanger sequencing as necessary.

This test provides full coverage of all coding exons of the GRIN2D gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define coverage as ≥20X NGS reads or Sanger sequencing.

Indications for Test

GRIN2D testing may be considered in patients with early infantile epileptic encephalopathy and developmental delay. Targeted testing is indicated for family members of patients who have a known pathogenic variant in GRIN2D.  


Official Gene Symbol OMIM ID
GRIN2D 602717
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


Name Inheritance OMIM ID
Epileptic Encephalopathy, Early Infantile, 46 AD 617162


  • Camp and Yuan. 2020. PubMed ID: 31918992
  • Hausman-Kedem et al. 2020. PubMed ID: 32289570
  • Li et al. 2016. PubMed ID: 27616483
  • Tsuchida et al. 2018. PubMed ID: 30280376
  • XiangWei et al. 2019. PubMed ID: 31504254
  • Yu et al. 2018. PubMed ID: 29317596


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.

Specimen Types

Specimen Requirements and Shipping Details

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard